The trial met its primary efficacy endpoint of mid-level performance of upper limb (mid-PUL v1.2) and various skeletal and cardiac function endpoints.
Young men in the advanced stages of DMD experienced improvements in skeletal and cardiac measurements after receiving four doses of CAP-1002 over one year.
The results showed that CAP-1002 demonstrated slowed disease progression by 71%.
PUL is a tool designed to assess high (shoulder), mid (elbow), and distal (wrist & hand) function.
Additional notable endpoints of full PUL v2.0 (p=0.04) and cardiac endpoint of ejection fraction (p=0.002). The final data efficacy analysis shows a change of 3.2 points for full PUL (v1.2) in CAP-1002 versus placebo at 12 months.
CAP-1002 was generally safe and well-tolerated.
Except for two hypersensitivity reactions early in the clinical trial, which were mitigated with a common pre-medication regimen, the HOPE-2 Data and Safety Monitoring Board (DSMB) identified no serious safety signals.
Capricor will host a conference call and webcast today at 8:30 a.m. ET to discuss the final data.
Price Action: CAPR stock is up 17.1% at $5.88 during the premarket session on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.